The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.

Arnulf StenzlRussell Z SzmulewitzDaniel PetrylakJeffrey HolzbeierleinArnauld VillersArun AzadAntonio AlcarazBoris AlekseevTaro IguchiNeal D ShoreFrancisco Gomez-VeigaCristina IvanescuBrad RosbrookKrishnan RamaswamyArijit GanguliGabriel P HaasAndrew J Armstrong

Published in: The Prostate (2022)

Enzalutamide plus ADT provides clinical benefits in defined patient subgroups versus ADT alone, while maintaining lack of pain and high HRQoL, with delayed deterioration in several HRQoL measures.

Keyphrases

prostate cancer
radical prostatectomy
chronic pain
squamous cell carcinoma
small cell lung cancer
case report
pain management
neuropathic pain
middle aged
spinal cord injury
spinal cord
patient reported
breast cancer risk